Detalhe da pesquisa
1.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272512
2.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
3.
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
Biol Blood Marrow Transplant
; 26(1): 204-208, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31446197
4.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(8): 1394-1401, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442725
5.
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Blood
; 129(25): 3294-3303, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28483761
6.
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Lancet Oncol
; 19(12): 1641-1653, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442502
7.
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biol Blood Marrow Transplant
; 24(4): 871-876, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29288818
8.
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Br J Haematol
; 180(6): 821-830, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435979
9.
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Biol Blood Marrow Transplant
; 22(2): 258-267, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26325439
10.
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Blood
; 124(6): 899-906, 2014 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24963043
11.
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.
Am J Hematol
; 96(6): E193-E196, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661527
12.
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Am J Hematol
; 91(6): 575-80, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26955792
13.
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Expert Opin Biol Ther
; : 1-12, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38738379
14.
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
Blood
; 127(19): 2355-6, 2016 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27020089
15.
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
J Immunother Cancer
; 11(5)2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37137553
16.
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
Leuk Lymphoma
; 63(9): 2126-2135, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35648041
17.
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
Blood Cancer J
; 12(2): 32, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35210399
18.
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
Cancer Immun
; 10: 4, 2010 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-20108890
19.
"Please Keep Mom Alive One More Day"-Clashing Directives of a Dying Patient and Her Surrogate.
J Pain Symptom Manage
; 59(5): 1147-1152, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32014529
20.
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Leukemia
; 34(12): 3298-3309, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32409691